People who take a commonly-prescribed drug for inflammatory bowel disease (IBD) should not assume they are protected after a first dose of Covid-19 vaccine, say the authors of a large-scale study that found many had poor antibody responses.
Daily Current Affairs Quiz 2021
The research measured antibody responses after vaccination with the Pfizer-BioNTech or the Oxford-AstraZeneca Covid-19 vaccine in 865 people treated with infliximab, an anti-tumour necrosis factor (anti-TNF) biologic drug, prescribed to around two million people worldwide.
One of the brand names under which infliximab is marketed is Remicade, which has got regulatory clearance in India.
Anti-TNF drugs are effective treatments for immune-mediated inflammatory diseases, but by suppressing the immune system, they can reduce vaccine effectiveness and increase risk of serious infection, the researchers have suggested.
